Background {#Sec1}
==========

Consumers increasingly rely on the Internet for their health information needs \[[@CR1]\]. A recent Pew Research Center survey found that among the 81% of U.S. adults who use the Internet, 72% have searched online for health information \[[@CR2]\]. The same survey revealed that consumers most frequently seek information about specific diseases and treatments (55%) and often self-diagnose using online resources (59%). About half of their searches are concerned with health information needs of family and friends, and most information-seeking activities start with a search engine query (77%).

While search engines have become increasingly sophisticated in retrieving information relevant to search queries, formulating a health information need in a few relevant query terms remains a challenging cognitive task for many consumers \[[@CR3]\]. Some research has suggested that short queries used by consumers are not effective in retrieving relevant information \[[@CR4], [@CR5]\]. Natural language questions allow the consumers to more fully express their health information needs. Consumers, when they fail to find information using search engines, often turn to online health forums and QA websites, where they can express their health concerns as natural language questions. While such resources are convenient for expressing complex health questions, they also present the additional challenge of *question understanding* for information retrieval systems. Question understanding can broadly be defined as the task of extracting relevant elements or generating a formal representation of a natural language question, which can then be used to formulate a query to a search engine and retrieve relevant answers (*answer retrieval*) \[[@CR6]\].

Most research in biomedical QA has focused on clinical questions asked by healthcare professionals \[[@CR7]\], which are often succinct and well-formed. In contrast, consumer health questions are rife with misspellings, ungrammatical constructions, and non-canonical forms of referring to medical terms, are fairly long with much background information and multiple sub-questions, and are closer to open-domain language than to medical language \[[@CR8]\]. To illustrate, consider the following email received by the customer service of the U.S. National Library of Medicine (NLM): *pls guide us.Dear sir/Madam pls guide us recently we found one of woman staying with us,she coughing and blood coming from mouth so she went to doctor on 2012 they did blood test and sputm test ct scan also they didnt find anything,recently she went to indonesia \[LOCATION\],they found repot was PROGRESSIVE DISEASE,ACTIVE LUNG TBINTHE RIGHT B2 AND B4 SEGMENS,THE EXUDATIVE LESIONS IS INCREASING WITH SMALL CAVITY.so what we have to do for her is this contages,who is the pople staying with her need to do test ?pls guide me thank u my contact \[CONTACT\]*

Three sub-questions can be distinguished: one regarding treatment options for lung tuberculosis, another asking whether this disease is contagious and the third asking how to get tested. The question includes background information that can be considered irrelevant for answer retrieval (that the patient saw a doctor in 2012 and travelled to Indonesia). It also contains spelling and grammar errors that would render it difficult to process with standard NLP tools. For example, the disease in question has a word break error and is abbreviated and *contagious* is misspelled, making both sub-questions very difficult to parse automatically. Based on such characteristics, it has been suggested that consumer health QA systems should be designed with considerations different from those underlying QA systems targeting healthcare professionals \[[@CR8]\].

NLM receives health-related questions and queries from a wide range of consumers worldwide. We have been developing a consumer health QA system to assist various NLM services in answering such questions. Question understanding is a core component of this system. As is typical with other NLP tasks, annotated corpora are needed to develop and evaluate automated tools addressing this task. Our earlier work relied on a small corpus \[[@CR9]\], which was sufficient for evaluating the narrow focus of the prototype system developed, but was not large enough to train QA systems. In other work, we relied on curated consumer health questions \[[@CR10], [@CR11]\]. In the present study, we aimed to address the gap by annotating a corpus of unedited, uncurated consumer health questions. We annotated 2614 consumer health questions with several semantic layers: named entities, question topic, question triggers, and question frames. The majority of the questions (67%) come from consumer health emails received by the the U.S. National Library of Medicine (NLM) customer service and are relatively long questions (Example [1](#Sec1){ref-type="sec"}). We refer to this subset as *CHQA-email*. The rest of the questions (33%) have been harvested from the search query logs of MedlinePlus, a consumer-oriented NLM website for health information, and are generally much shorter (*CHQA-web*). Despite being posed as search queries, these questions are expressed as natural language questions, rather than keywords. An example question from CHQA-web is provided below: (2)*what teeth are more likely to get cavities?*

In a previous study, we annotated a subset of the questions in CHQA-email with named entities \[[@CR12]\]. The present study builds upon and significantly extends that work. Here, we describe corpus characteristics, annotation schemes used, annotation steps taken, and statistics on the resulting dataset. Additionally, we report a small study to automatically assess confidence of annotations, when annotation adjudication can be impractical. We make the resulting annotated corpus publicly available at <https://bionlp.nlm.nih.gov/CHIQAcollections/CHQA-Corpus-1.0.zip>. To our knowledge, the corpus is unique for its focus on uncurated consumer health questions and the level and breadth of semantic detail it incorporates. We believe that, with its size and coverage, it can stimulate further research in consumer health QA.

Related work {#Sec2}
============

Corpus construction and annotation has been critical for the progress made in NLP in the past several decades \[[@CR13]--[@CR15]\]. Biomedical NLP has also benefitted significantly from numerous domain-specific corpora annotated for linguistic and semantic information. Most annotation efforts have focused on biomedical literature and clinical reports and a small number on other text types such as drug labels and social media text. The types of information annotated have ranged from syntactic structure \[[@CR16], [@CR17]\] to semantic phenomena, including named entities/concepts \[[@CR18]--[@CR22]\], relations/events \[[@CR19], [@CR23]--[@CR25]\], assertion/uncertainty/negation \[[@CR19], [@CR26]\], coreference \[[@CR27]--[@CR29]\], and rhetorical structure \[[@CR30], [@CR31]\]. Community-wide shared task competitions have relied on such corpora to advance the start-of-the-art in biomedical NLP \[[@CR19], [@CR32]--[@CR35]\].

Most biomedical QA research has focused on information needs of healthcare professionals, and several corpora have been used for this purpose. The Clinical Questions Collection, maintained by the NLM, is a repository of 4654 questions collected by Ely et al. \[[@CR36]\] and D'Alessandro et al. \[[@CR37]\] at the point of care. Original questions, their short and general forms, their topics (e.g., *management*, *diagnosis*, *epidemiology*), keywords (e.g., *Polymenorrhea*, *Menstruation Disorders*) as well as physician and patient information are provided. This collection has been used to develop several machine learning-based QA systems, such as AskHERMES \[[@CR38]\] and MiPACQ \[[@CR39]\]. Other smaller corpora also exist; for example, Parkhurst Exchange and Journal of Family Practice[1](#Fn1){ref-type="fn"} maintain curated question sets that have been used to develop CQA, a clinical QA system based on evidence-based medicine principles \[[@CR40]\]. Patrick and Li \[[@CR41]\] presented a set of 446 clinical questions from staff in an intensive care unit asking for patient-specific information from their electronic health records and created a question taxonomy based on answering strategies. Text REtrieval Conference (TREC) Genomics track provided a platform to study QA for biological research \[[@CR42]\]. A set of 36 questions asking for lists of specific entities (antibodies, pathways, mutations, etc.) was manually developed to represent the information needs of the biologists (e.g., *What \[MUTATIONS\] in the Raf gene are associated with cancer?*). More recently, BioASQ challenge also focused on biomedical QA and presented a corpus of 311 questions, categorized by the type of answers they require: yes/no, factoid, list, and summary \[[@CR43]\].

Two approaches to modeling and formally representing biomedical questions have been distinguished: empirical and domain-based models \[[@CR6]\]. In the empirical approaches, the questions are categorized into a limited number of generic question types \[[@CR36], [@CR41], [@CR44]\]. Domain-based models provide a high-level definition of the main entities and actors in the domain and their relationships. For example, the PICO framework represents the elements of a clinical scenario with four elements, population/problem (P), intervention (I), comparison (C), outcome (O), and has been used as the basis of the CQA system \[[@CR40]\]. Other formal approaches have also been used to represent clinical questions; for example, they have been represented as concept-relation-concept triples \[[@CR45], [@CR46]\], Description Logic expressions \[[@CR47]\], SPARQL queries \[[@CR48]\], and *λ*-calculus expressions \[[@CR49]\].

Early research on consumer health information seeking focused on analysis of consumer health queries \[[@CR4], [@CR50]\]. Based on the finding that such queries are not effective in finding relevant information \[[@CR4], [@CR5]\], several other small-scale studies specifically analyzed consumer health questions \[[@CR3], [@CR51]--[@CR53]\]. For example, Zhang \[[@CR3]\] analyzed 276 health-related questions submitted to Yahoo! Answers, a community QA website, on several dimensions, including linguistic style and motivation, and found that these questions primarily described diseases and symptoms (accompanied by some patient information), were fairly long, dense (incorporating more than one question), and contained many abbreviations and misspellings. Slaughter et al. \[[@CR52]\] manually annotated the semantics of a small number of consumer health questions and physician answers using Unified Medical Language System (UMLS) Semantic Network and found that both patients and physicians most commonly expressed causal relationships. More recently, Roberts and Demner-Fushman \[[@CR8]\] studied how consumer questions differed from those asked by professionals and analyzed 10 online corpora (5 consumer, 5 professional, including some that have been discussed above) at lexical, syntactic, and semantic levels using a variety of NLP techniques. Their findings largely mirror those of Zhang \[[@CR3]\]. Additionally, they found substantial differences between consumer corpora and showed that consumer health questions are closer to open-domain language than to medical language. Based on these findings, they suggest that consumer health QA systems need to be designed with a different set of considerations, instead of naively adapting a professional QA system. Liu et al. \[[@CR54]\] developed a SVM classifier to distinguish consumer health questions from professional questions, and used questions from Yahoo! Answers and the Clinical Questions Collection for training.

We developed several consumer health corpora in the context of our consumer health QA project. In early work, we used a small set of 83 consumer health questions about diseases/conditions (mostly genetic), which consisted of relatively simple questions received by the NLM customer service and frequently asked questions collected from Genetic and Rare Disease Information Center (GARD)[2](#Fn2){ref-type="fn"}, to develop a rule-based approach to extract question type and question theme \[[@CR9]\]. GARD also formed the basis of annotation of 13 question types on 1,467 questions focusing on genetic diseases \[[@CR10]\]. These question types include *anatomy* (location of a disease), *cause* (etiology of a disease), *information* (general information about a disease), and *management* (treatment, management, and prevention of a disease), among others. The average inter-annotator agreement (Cohen's *κ*) for question types was found to be 0.79 (substantial agreement). Recognizing that consumer health questions are complex with multiple sub-questions related by a central theme (focus), Roberts et al. \[[@CR11]\] also annotated the same GARD dataset with question focus and question decomposition, where individual sub-questions are identified within complex questions, and each sub-question is annotated for several elements, including the central theme (*focus*), contextual information (*background*) and the actual question, at sentence and phrase levels. *Background* sentences were further classified into one of several medical categories, such as diagnosis, symptoms, or family history. The average inter-annotator agreement was found to be 0.91 for *focus* and 0.72 for *background* class. These GARD-based datasets have been used to train and evaluate question type classifiers \[[@CR55]\] as well as focus recognizers and question decomposition classifiers \[[@CR56], [@CR57]\]. The questions in the GARD dataset, even though they were asked by consumers, are curated; thus, they are well-formed with few misspellings, and represent an intermediate step between simple questions addressed in \[[@CR9]\] and the more typical, complex consumer health questions. Consequently, while good classification performance is reported on the GARD dataset, performance drops significantly on the more complex questions received by NLM \[[@CR57]\]. To address this gap, in recent years, we focused on annotation of uncurated consumer health questions received by NLM, without any simplifying assumptions. Considering that misspellings are a major obstacle in question understanding and that off-the-shelf spelling correction tools do not work well on customer health questions, we developed a spelling correction dataset that consists of 472 NLM questions \[[@CR58]\]. In this dataset, we annotated non-word, real word, punctuation, as well as word break errors. We also developed an ensemble method that uses edit distance, corpus frequency counts, and contextual similarity to correct misspellings. Finally, we created a dataset of 1548 questions taken from the same resource, de-identified them for personal health information, and annotated them for named entities (CHQ-NER) \[[@CR12]\]. Each question was double-annotated using 16 named entity types (e.g., [ANATOMY]{.smallcaps}, [DRUG_SUPPLEMENT]{.smallcaps}, [PROBLEM]{.smallcaps}, [PROCEDURE_DEVICE]{.smallcaps}, [PERSON_ORGANIZATION]{.smallcaps}), determined based on a round of practice annotation. The annotation was performed in both manual and assisted mode, in which existing named entity recognition tools were used to pre-annotate questions. After double-annotation of questions, they were reconciled by one of the expert annotators.

Moderate agreement (0.71 F~1~ agreement with exact matching) was achieved, with slightly higher agreement in assisted mode (0.72).

Methods {#Sec3}
=======

In this section, we first describe our approach to representing consumer health questions. Next, we discuss corpus construction and the semantic annotation that we performed on this corpus in depth. We conclude this section by providing details on our attempt to automatically estimate confidence scores of semantic annotations, when full adjudication is not feasible due to personnel/time constraints.

Question representation {#Sec4}
-----------------------

We briefly discussed several approaches to biomedical question representation above: empirical, domain-based, and formal. Our approach to representing consumer health questions can be viewed as a hybrid method. Like empirical approaches, we begin with existing questions and categorize them into a limited number of generic question templates, and, like formal approaches, we create structured representations of the information in these generic questions that we call *question frames*. Frame representation is similar to a predicate-argument structure, a semantic representation in which a predicate is linked to its arguments and the semantic roles of the arguments, such as [THEME]{.smallcaps} and [AGENT]{.smallcaps}, are specified \[[@CR59]\]. A question frame consists of a question trigger indicating the question type (similar to predicate), one or more [THEME]{.smallcaps} arguments, and a set of optional arguments with other semantic roles, all linked to their textual mentions. All arguments of a frame correspond to named entities. Each sub-question in a consumer health question is represented with a separate frame. To illustrate, consider the question we discussed earlier, reproduced in Example 3. An example representation of this question consists of the frames in Table [1](#Tab1){ref-type="table"}. (3)*pls guide us.* Table 1Frame representation of the question in Example 3Frame 1Question type*do*:[treatment]{.smallcaps}Theme*ACTIVE LUNG TB*: [problem]{.smallcaps}Frame 2Question type*contages*:[susceptibility]{.smallcaps}Theme*ACTIVE LUNG TB*: [problem]{.smallcaps}Frame 3Question type*test*:[diagnosis]{.smallcaps}Theme*ACTIVE LUNG TB*: [problem]{.smallcaps}The question is represented with three frames, each composed of two elements, question type and theme. The content of each element is shown as a mention:TYPE pair*Dear sir/Madam pls guide us recently we found one of woman staying with us,she coughing and blood coming from mouth so she went to doctor on 2012 they did blood test and sputm test ct scan also they didnt find anything,recently she went to indonesia \[LOCATION\],they found repot was PROGRESSIVE DISEASE,ACTIVE LUNG TBINTHE RIGHT B2 AND B4 SEGMENS,THE EXUDATIVE LESIONS IS INCREASING WITH SMALL CAVITY.so what we have to do for her is this contages,who is the pople staying with her need to do test ?pls guide me thank u my contact \[CONTACT\]*

The first frame indicates that the information request contains a question about the treatment of active lung tuberculosis, triggered by the verb *do* in *what we have to do for her*. Note that while a [THEME]{.smallcaps} argument is required for each frame, we only specify other arguments if they are likely to be relevant for answer retrieval. For example, in the first frame, one could specify *woman* as an argument with [PATIENT]{.smallcaps} role (i.e., the person to undergo treatment); however, since gender is unlikely to be significant in answering this particular question, its explicit representation is not required. In this sense, our representation is driven more by pragmatic concerns for question answering than by completeness.

Our prior research suggested that when the question topic[3](#Fn3){ref-type="fn"} (often the [THEME]{.smallcaps} of a sub-question) and the question types in an information request are known, authoritative answers can be found in 60% of the cases \[[@CR60]\]. Taking this into account, we also explicitly indicate the question topic in question representation. The question topic is indicated as a named entity attribute. In the question above, the named entity corresponding to the mention *ACTIVE LUNG TB* is marked as the question topic. The annotation of this question is illustrated in Fig [1](#Fig1){ref-type="fig"}. Fig. 1*Brat* annotation for the consumer health question in Example 3. Named entities and question triggers are indicated with text spans and the question frames are represented as edges between the question trigger and named entities that act as arguments. Question topic (*ACTIVE LUNG TB*) is indicated with (F) next to its named entity category. Named entity categories are sometimes abbreviated: [ANATOMY]{.smallcaps} (Anat), [DIAGNOSTIC_PROCEDURE]{.smallcaps} (DiaP), [GEOGRAPHIC_LOCATION]{.smallcaps} (GeoL), [PERSON_POPULATION]{.smallcaps} (Pers), [PROFESSION]{.smallcaps} (Prof), [SUBSTANCE]{.smallcaps} (Subt). For question type categories, the abbreviated forms are: [DIAGNOSIS]{.smallcaps} (DIAG), [SUSCEPTIBILITY]{.smallcaps} (SUSC), and [TREATMENT]{.smallcaps} (TRTM)

Corpus construction and annotation {#Sec5}
----------------------------------

Our corpus consists of two parts: a set of 1740 questions harvested from consumer health emails received by the NLM customer service between 2013 and 2015 (CHQA-email) and another set of 874 questions harvested from MedlinePlus search query logs (CHQA-web).

### CHQA-email {#Sec6}

CHQA-email is an extension of an earlier corpus (CHQ-NER), reported in \[[@CR12]\], and supersedes it. That corpus consisted of 1548 consumer health information requests received by the NLM customer service in 2014-15 and manually labeled as disease and drug questions by the staff. These requests were annotated for named entities. For details of the question selection procedure, see \[[@CR12]\]. Protected health information (PHI), such as names, locations, contact information, has been manually replaced with surrogates in these questions.

As part of the present study, we extended CHQ-NER with 195 additional questions. Furthermore, 2 duplicate questions and 1 non-question request from the original corpus were dropped, bringing the total number of questions to 1740. One hundred fourty six of the new questions come from the set of 300 questions that were considered in a study that investigated whether authoritative answers to consumer health questions can be found in MedlinePlus and other online resources \[[@CR60]\]. In that study, question types and topics were marked. Fourty nine questions came from a set which we used for an earlier, experimental annotation of question type, focus, and frames (unpublished). We incorporated existing annotations in these sets as pre-annotations to be used in subsequent steps. Both these additional sets of questions were then de-identified and annotated with named entities, following the guidelines for CHQ-NER \[[@CR12]\]. One expert annotator (SES) performed the annotation, she and another expert (DDF) then discussed and adjudicated these named entity annotations. At this stage, all 1740 questions had been fully annotated for named entities.

The rest of annotation of this part of the corpus proceeded as follows: first, all annotators annotated 20 questions for the elements under consideration (question topics, triggers/types, and frames). As the question type categories, we used those that were used in annotating GARD questions \[[@CR10]\]. As this step was exploratory and included drug questions which we had not considered before, we allowed the annotators to propose additional question types. Six annotators were involved in this practice step. After a round of discussion and adjudication, we extended the question type categorization, defined three semantic roles ([THEME]{.smallcaps}, [KEYWORD]{.smallcaps}, and [EXCLUDE_KEYWORD]{.smallcaps}), and prepared annotation guidelines. We did not calculate inter-annotator agreement for these practice questions and only make available the final, adjudicated annotations.

Next, we sliced the rest of corpus (1720 questions) such that each annotator was allocated roughly the same number of questions, and each shared with all the other annotators approximately the same number of questions. Seven annotators were involved, although the additional annotator (Ann7) annotated significantly fewer than the others due to scheduling conflicts. The questions initially allocated to her but could not be annotated were redistributed among four annotators in such a way to ensure that each question was still double-annotated and the questions were fairly distributed. The resulting number of questions annotated by each annotator is given in Table [2](#Tab2){ref-type="table"}. At this step, the annotators were allowed to modify the original named entity annotations if they deemed it necessary for topic/frame annotation. After this step was completed, we automatically checked the annotations for consistency, which involved addressing two common problems observed in annotation: first, we ensured that each question contained a question topic annotation and second, we checked that each frame contained a single [THEME]{.smallcaps} argument, except when the question type is one that allows multiple [THEME]{.smallcaps} arguments, such as [COMPARISON]{.smallcaps}. Table 2The number of questions annotated by each annotator in CHQA-emailAnnotator\# questionsAnn1565Ann2495Ann3553Ann4489Ann5554Ann6544Ann7240

We calculated inter-annotator agreement for question triggers/types, frames with and without optional elements, and question topic. Inter-annotator agreement is calculated as the micro-average F~1~ score when one set of annotations is considered the gold standard \[[@CR61]\].

Considering the length of questions, the average number of annotations per question, and the number of annotators involved, adjudicating this set is a daunting task[4](#Fn4){ref-type="fn"}. Therefore, instead of adjudication, we chose to investigate whether confidence scores can be automatically estimated for annotations. More details about this process are given at the end of this section.

### CHQA-web {#Sec7}

In contrast to CHQA-email, the second part of the corpus, CHQA-web, has been fully annotated from scratch in this study. MedlinePlus provides search capabilities that are geared towards traditional keyword searches; however, a significant number of searches are posed as natural language questions. Such searches often fail. To investigate whether we can address such questions automatically and to create a counterpoint to customer service information requests, we harvested a set of short questions from MedlinePlus search query logs. These questions were asked in the period from May 2015 to April 2016. We looked for *wh*-words to identify these questions in the query logs: *how, what, when, where, which, who, why*. We also included queries ending with question marks and those that start with an auxiliary (*is it, can, could, do, does*). For each category, we selected 70 most frequent questions as well as 70 random questions. After removing duplicates and near-duplicates using string matching heuristics, we were left with 1180 questions. In contrast to CHQA-email, we did not assess whether these were all legitimate questions or were answerable; instead, we used two labels, [NOT_ANSWERABLE]{.smallcaps} and [NOT_QUESTION]{.smallcaps}, during the annotation process to mark such questions. Recognizing that our heuristics for removing duplicates may not be adequate, we used another label, [DUPLICATE]{.smallcaps}, to indicate such cases.

In a practice step, the same six annotators annotated and adjudicated 100 of these questions using the guidelines for CHQA-email. During this process, the guidelines were updated: some question types were consolidated, a couple of new types were added, and the types of semantic roles were expanded.

Next, four of the annotators double-annotated the rest of the questions (n=1,080). Instead of pairing all annotators, we only paired those with clinical expertise (n=2) with those without (n=2), leading to four annotator combinations. In the end, each annotator labeled 540 questions. Since these questions were relatively short and there were fewer annotator pairs, we chose to adjudicate these annotations. Each pair adjudicated the questions that they both annotated. As in CHQA-email, we calculated inter-annotator agreement using micro-average F~1~ score. Fourty eight questions were adjudicated as [NOT_QUESTION]{.smallcaps}, 203 were deemed [NOT_ANSWERABLE]{.smallcaps} and 55 were found to be [DUPLICATE]{.smallcaps}, bringing the total number of annotated questions in this part down to 874.

### Annotation {#Sec8}

Seven annotators participated in various stages of the annotation, depending on their availability. All annotators had experience in working with biomedical text. Two annotators (LR, DDF) have clinical expertise, two are trained as medical librarians (SES, KM), and four have experience in natural language processing (HK, ABA, YM, and DDF). We used *brat* annotation tool \[[@CR62]\] for all stages of annotation. Named entities and question triggers were annotated as terms, and frames were annotated as events in *brat*. Question topic was specified as an attribute of the relevant named entity.

In the rest of this subsection, we provide details about annotation of these semantic layers and highlight the differences in their annotation between the two parts of the corpus.

#### Named entity annotation {#Sec9}

Named entity annotation in CHQA-email essentially follows the principles of CHQ-NER \[[@CR12]\].

In CHQ-NER, we annotated 16 broad categories of named entities ([ANATOMY]{.smallcaps}, [CELLULAR_ENTITY]{.smallcaps}, [DIAGNOSTIC]{.smallcaps}[\_PROCEDURE]{.smallcaps}, [DRUG]{.smallcaps}[\_SUPPLEMENT]{.smallcaps}, [FOOD]{.smallcaps}, [GENE]{.smallcaps}[\_PROTEIN]{.smallcaps}, [GEOGRAPHIC_LOCATION]{.smallcaps}, [LIFESTYLE]{.smallcaps}, [MEASUREMENT]{.smallcaps}, [ORGANIZATION]{.smallcaps}, [PERSON_POPULATION]{.smallcaps}, [PROBLEM]{.smallcaps}, [PROCEDURE]{.smallcaps}[\_DEVICE]{.smallcaps}, [PROFESSION]{.smallcaps}, [SUBSTANCE]{.smallcaps}, and [OTHER]{.smallcaps}). Nested entities and multi-part, non-contiguous annotations were allowed. Annotation was performed both manually and with assistance from several named entity recognizers \[[@CR63]--[@CR65]\].

For the present study, recognizing that many of the entities with [OTHER]{.smallcaps} type corresponded to physiological functions (e.g. *pregnancy*), we added a new named entity type [ORGANISM_FUNCTION]{.smallcaps}. We use the UMLS \[[@CR66]\] definition for Organism Function semantic type for this new category: "A physiologic function of the organism as a whole, of multiple organ systems, or of multiple organs or tissues". To ensure that annotations are consistent, one of the annotators (DDF) examined all strings annotated as [OTHER]{.smallcaps} in CHQ-NER and identified those that can be considered organism functions. We then automatically relabeled these mentions, originally labeled [OTHER]{.smallcaps}, as [ORGANISM_FUNCTION]{.smallcaps} in CHQA-email.

For CHQA-web, we considered 18 categories: 16 categories above in addition to [ORGANISM_FUNCTION]{.smallcaps} and [RESEARCH_CUE]{.smallcaps}. The latter, though not common, is a category that was devised to indicate that the consumer is interested in information that goes beyond typical consumer health information.

Example [RESEARCH_CUE]{.smallcaps} mentions include *new* and *latest information*. In contrast to CHQA-email, we did not consider nested entities for CHQA-web, as the annotators generally found the annotation of nested entities challenging, although such entities can provide a more precise evaluation for named entity recognizers, as illustrated in \[[@CR12]\].

The full list of named entity categories used in annotation, with brief definitions, examples, and relevant UMLS semantic types, is provided in Table [3](#Tab3){ref-type="table"}. Table 3Named entity categories with definitions, examples, and relevant UMLS semantic typesEntity typeBrief definitionExamplesUMLS semantic types*Named entity categories from* \[[@CR12]\][anatomy]{.smallcaps}Includes organs, body parts, and*head*, *neck*, *gum*Body System,tissues.Anatomical Structure[cellular_entity]{.smallcaps}Includes anatomical entities at the*hemoglobin*,Cell,molecular or cellular level.*giant cell*Cell Component[diagnostic\_]{.smallcaps}Includes tests and procedures used*biopsy*, *hemoglobin*,Diagnostic Procedure,[procedure]{.smallcaps}for diagnosis*iron levels*Laboratory Procedure[drug_supplement]{.smallcaps}Includes substances used for*atenolol*,Clinical Drug,therapeutic purposes.*atenolol 50 mg*,Vitamin*campho-phenique*[food]{.smallcaps}Refers to specific nutritional*eggs*, *breads*, *meat*Foodsubstances.[gene_protein]{.smallcaps}Includes specific genes and gene*BRCA1*,Gene or Genome,products.*BRCA1 gene*,Enzyme*GLUT4 protein*[geographic\_]{.smallcaps}Includes countries, cities, etc.*India*, *Singapore*Geographic Area[location]{.smallcaps}[lifestyle]{.smallcaps}Refers to daily and recreational*smoking*, *yoga*Daily or Recreationalactivities.Activity[measurement]{.smallcaps}A quantity that is a core attribute of a named entity, such as dosage of a drug.*10mg*, *2%*Quantitative Concept[organization]{.smallcaps}Includes institutions as well as their*navy*, *California*Organizationsubparts.*Hospitals*[person\_]{.smallcaps}Includes individuals (gender, age*daughter*, *female*,Age Group,[population]{.smallcaps}group, etc.) and population groups.*war veteran*,Population Group*16 year old*[problem]{.smallcaps}Includes disorders, symptoms,*HIV*, *cholesterol*,Disease or Syndrome,abnormalities, and complications.*broke*,Neoplastic Process*autoimmune disease*[procedure_device]{.smallcaps}Refers to procedures or medical*shingles treatment*,Medical Device,devices used for therapeutic*nephrolithotomy*,Therapeutic orpurposes as well as unspecific*implants*Preventive Procedureinterventions.[profession]{.smallcaps}Includes occupations, disciplines, or*dermatologist*, *dr*,Professional orareas of expertise.*surgeon*Occupational Group[substance]{.smallcaps}Includes chemicals, hazardous*iron*, *cholesterol*,Inorganic Chemical,substances, and body substances.*blood*, *alcohol*Biologically ActiveSubstance[other]{.smallcaps}Includes entities that are relevant to*more than once*Temporal Conceptquestion understanding, but do notfit in one of the categories above.*Named entity categories added in the present study*[organism_function]{.smallcaps}Refers to physiological functions of the organism.*pregnancy*Organism Function[research_cue]{.smallcaps}Indicates that consumer is interested in research information.*new*, *latest information*Qualitative Concept

#### Question topic annotation {#Sec10}

Question topic is the central theme (a disease, a drug, etc.) of a question. Each legitimate question is expected to have at least one topic, but multiple topic elements can be annotated, especially in questions about relationships between two diseases or drugs. In the earlier example, *ACTIVE LUNG TB* is the question topic, while there are two topics in the following question in bold: (4)*I'd like to learn more about* ***megalocytic interstitial nephritis*** *with* ***malakoplakia***.

All mentions of the topic term, including synonyms and misspellings, were expected to be annotated. For example, in the following question, synonyms *anosmia* and *loss of smell* are both legitimate topics. (5)***ANOSMIA***.*This site tells me that ongoing research may solve my problem some day. Please, could I be informed if such result does happen? I live alone, aged 78, and this complete* ***loss of smell*** *has been my great problem for quite a while.*

When considering nested entities for question topics, annotators were instructed to label the term as topic at the nesting level that is appropriate for the question. For example, in the following question, both mentions of *ropinirole HCl* as well as *repinirole HCl 0.25 mg* and *ropinirole HCl 0.5 mg* were annotated as named entities. With this instruction, annotators were expected to label mentions of *ropinirole HCl* as the topic, since the dosage/form of this drug is not relevant to the primary question. (6)*Ropinirole HCl 0.25 and ropinirole HCl 0.5 mg. Please tell me if these meds are gluten-free.*

These principles applied to question topic annotation in CHQA-email. For short questions in CHQA-web, based on the practice annotation, we chose not to explicitly annotate question topic, since this almost always corresponded to the [THEME]{.smallcaps} argument of the question frame.

#### Question type annotation {#Sec11}

We based our practice annotation of CHQA-email on the 14 question type categories proposed for disease questions in \[[@CR10]\]. Discussion/adjudication of practice questions led to an expanded set of 33 categories. These 33 categories can be analyzed in three distinct groups. *General question types:* These categories can apply to any type of entity ([comparison]{.smallcaps}, [information]{.smallcaps}, and [other_question]{.smallcaps}).*Problem question types:* These categories apply to diseases/conditions, and other problems (e.g., [cause]{.smallcaps}, [complication]{.smallcaps}, [diagnosis]{.smallcaps}, [inheritance]{.smallcaps}, [prognosis]{.smallcaps}, and [treatment]{.smallcaps}). A subset of these categories also apply to entities of procedure and medical device types, since problems can arise from their usage (e.g., [complication]{.smallcaps}, [prognosis]{.smallcaps}, and [support_group]{.smallcaps}).*Intervention question types:* These categories apply to drugs, supplements, as well as procedures and medical devices (e.g., [action]{.smallcaps}, [indication]{.smallcaps}, [side_effect]{.smallcaps}, and [usage]{.smallcaps}).

We provide some further details in Table [4](#Tab4){ref-type="table"}. The last column indicates whether the question type was among the 14 categories proposed by Roberts et al. \[[@CR10]\]. Table 4Question type categories in CHQA-email with their definitions and some commonly used triggersQuestion typeBrief definitionExample triggersIn \[[@CR10]\]*General question types*[comparison]{.smallcaps}Concerned with comparison of several entities (often of the same type)*comparison*, *differences*[information]{.smallcaps}General information about an entity*information*, *types*✓[other_question]{.smallcaps}Information not covered with other types*prepare*, *cover*✓*Problem question types*[cause]{.smallcaps}Cause of a disease*cause*, *trigger*✓[complication]{.smallcaps}\*Longer term effects of a disease*risk*, *damage*✓[diagnosis]{.smallcaps}Methods of diagnosing a disease*diagnose*, *detection*✓[effect]{.smallcaps}\*Unspecific effects of a disease*affect*, *link*, *related*✓(a)[frequency]{.smallcaps}Prevalence of a disease*statistics*, *prevalence*✓(b)[inheritance]{.smallcaps}Inheritance patterns of a disease*passed*, *genetic*✓(b)[lifestyle_diet]{.smallcaps}\*Lifestyle/diet changes after a disease*okay*, *precautions*[location]{.smallcaps}\*Body location of a disease*areas*, *occur*✓(c)[person_organization]{.smallcaps}\*Individuals/organizations specializing in a disease*find*, *consult*✓(d)[prevention]{.smallcaps}Methods of prevention for a disease*prevent*, *save from*✓(e)[prognosis]{.smallcaps}\*Life expectancy and quality of life for a disease*recovery*, *how long*✓[support_group]{.smallcaps}\*Support groups for a disease*support groups*, *recommend*✓(d)[susceptibility]{.smallcaps}Transmission of a disease*transmitted*, *spread*✓[symptom]{.smallcaps}Signs and symptoms of a disease*symptom*, *normal*✓(f)[treatment]{.smallcaps}Treatment, cure, management of a disease*cure*, *help*, *improve*✓(e)*Intervention question types*[action]{.smallcaps}How a drug acts in the body*start working*[alternative]{.smallcaps}Alternatives for an intervention*alternative*, *replacement*[contraindication]{.smallcaps}Conditions in which an intervention should be avoided*take if*, *hurt*[cost]{.smallcaps}Pricing of an intervention*cost*, *rate*[dosage]{.smallcaps}Appropriate dosage of a drug*dosage*, *administration*[indication]{.smallcaps}Conditions to use an intervention*for*, *given to*[ingredient]{.smallcaps}Ingredients of a drug*in*, *made from*[interaction]{.smallcaps}Interactions between drugs*reaction*, *safe to take*[long_term_effect]{.smallcaps}Long term consequences of an intervention*cause*, *long term effect*[overdose]{.smallcaps}Consequences of a substance overdose*do*, *hurt*[side_effect]{.smallcaps}Short-term, adverse reactions to an intervention*side effect*, *poisonous*[storage_disposal]{.smallcaps}Instructions for storing/disposing a drug*expire*, *stability*[tapering]{.smallcaps}Instructions for how to stop using a drug*weaning*, *withdrawal*[usage]{.smallcaps}Patient instructions for an intervention*applying*, *take*[drug_question]{.smallcaps}Other intervention question (e.g., drug form)*come in*, *potent*Notes: (\*) Applies to procedures/medical devices, as well. (a) As [other_effect]{.smallcaps}. (b) As [susceptibility]{.smallcaps}. (c) As [anatomy]{.smallcaps}. (d) As [person_org]{.smallcaps}. (e) As [management]{.smallcaps}. (f) As [manifestation]{.smallcaps}

For question type annotation in CHQA-web, this scheme was modified in several ways, resulting in a somewhat simplified categorization that consists of 26 classes. First, some question types that do not occur frequently were merged into other categories that can be considered their supertypes. For example, in CHQA-email annotation, we split the question type [SUSCEPTIBILITY]{.smallcaps} as defined in Roberts et al. \[[@CR10]\] into three types that address different but related characteristics of diseases: [FREQUENCY]{.smallcaps}, [INHERITANCE]{.smallcaps}, and [SUSCEPTIBILITY]{.smallcaps}. Considering that answers to such questions are likely to be found in the same passages, for annotation convenience and expediency, we merged these types back into [SUSCEPTIBILITY]{.smallcaps} in CHQA-web. The consolidated question types are the following: [{complication, long_term_effect, overdose, side_effect}]{.smallcaps} →[complication]{.smallcaps}[{person_organization, support_group}]{.smallcaps} →[person_organization]{.smallcaps}[{frequency, inheritance, susceptibility}]{.smallcaps} →[susceptibility]{.smallcaps}[{dosage, storage_disposal, tapering, usage}]{.smallcaps} →[usage]{.smallcaps}

We generalized the question type [EFFECT]{.smallcaps} to indicate underspecified relations between two or more named entities, and changed its name to [ASSOCIATION]{.smallcaps} for clarity. Finally, we added two new question types. [DIAGNOSE_ME]{.smallcaps} identifies questions asking for diagnosis from a set of symptoms. For example, this question type was annotated for the following question (the trigger is in bold). (7)*my waist turn red like i have hives but it's not and its not achy or itchy,* ***what*** *do u think* ***it is***?

While we specifically avoided annotating such questions in CHQA-email, since they were considered beyond the scope of a QA system provided by a medical library, we added such annotations in CHQA-web to allow further experiments. The other question type, [TIME]{.smallcaps}, identifies questions asking for time/duration of an event. An example is given below. (8)*who gets vaccines and* ***when***?

The annotators were instructed to annotate the minimal trigger expression, except when two equally valid triggers are conjoined. In the first question in Example [1](#Sec11){ref-type="sec"}, the question trigger is *take*, rather than *can take* or *if I can take*. In the second question, since both *reduce* and *remove* can trigger the same question type, the question trigger is taken as *reduce or remove*. (9)*I would like to ask if I can* ***take*** *glutathione supplement.fibroadenomas....taking medicine is help to* ***reduce or remove*** *this?...*

#### Question frame annotation {#Sec12}

In CHQA-email, question frames were annotated using the 17 named entity categories and 33 question types discussed above. A question frame in this context minimally consists of two elements: a trigger indicating the question type and a [THEME]{.smallcaps} argument, which corresponds to a named entity. The type of the question frame is inherited from the trigger. Most questions types allow a single [THEME]{.smallcaps} argument, with the exceptions of [EFFECT]{.smallcaps}, which allows multiple [THEME]{.smallcaps} arguments, and [COMPARISON]{.smallcaps}, which requires multiple [THEME]{.smallcaps} arguments. Restrictions on the type of named entities that can fill the [THEME]{.smallcaps} role are specified in Table [5](#Tab5){ref-type="table"}. Table 5Restrictions on [THEME]{.smallcaps} arguments in CHQA-emailQuestion typesTheme restrictions*General question types*[comparison]{.smallcaps}[entity]{.smallcaps}{2,}[information]{.smallcaps}, [other_question]{.smallcaps}[entity]{.smallcaps}*Problem question types*[cause]{.smallcaps}, [diagnosis]{.smallcaps}, [frequency]{.smallcaps}, [inheritance]{.smallcaps}, [prevention]{.smallcaps}, [susceptibility]{.smallcaps}, [symptom]{.smallcaps}, [treatment]{.smallcaps}[problem]{.smallcaps}[complication]{.smallcaps}[problem]{.smallcaps}, [procedure_device]{.smallcaps}, [lifestyle]{.smallcaps}, [food]{.smallcaps}[effect]{.smallcaps}[problem]{.smallcaps}+, [procedure_device]{.smallcaps}+[lifestyle_diet]{.smallcaps}, [location]{.smallcaps}, [prognosis]{.smallcaps}[problem]{.smallcaps}, [procedure_device]{.smallcaps}[person_organization]{.smallcaps}, [support_group]{.smallcaps}[problem]{.smallcaps}, [procedure_device]{.smallcaps}, [diagnostic_procedure]{.smallcaps}*Intervention question types*[action]{.smallcaps}, [dosage]{.smallcaps}, [drug_question]{.smallcaps}, [ingredient]{.smallcaps}, [overdose]{.smallcaps}[drug_supplement]{.smallcaps}, [substance]{.smallcaps}[alternative]{.smallcaps}, [cost]{.smallcaps}, [indication]{.smallcaps}, [long_term_effect]{.smallcaps}, [side_effect]{.smallcaps}, [usage]{.smallcaps}[drug_supplement]{.smallcaps}, [substance]{.smallcaps},[procedure_device]{.smallcaps}, [diagnostic_procedure]{.smallcaps}[contraindication]{.smallcaps}, [storage_disposal]{.smallcaps}, [tapering]{.smallcaps}[drug_supplement]{.smallcaps}, [substance]{.smallcaps}, [procedure_device]{.smallcaps}[interaction]{.smallcaps}[drug_supplement]{.smallcaps}{2,}, [substance]{.smallcaps}{2,}{2,} indicates cardinality of at least two, + indicates at least one argument

In CHQA-web, question frame annotation involved 26 question types and 18 named entity categories. We lifted the type restrictions for theme arguments for this part of the corpus, because the annotators found them too restrictive. However, the cardinality restrictions remained in place. For example, [INTERACTION]{.smallcaps} still required at least two [THEME]{.smallcaps} arguments. Two additional question types, [DIAGNOSE_ME]{.smallcaps} and [TIME]{.smallcaps}, were allowed multiple themes and a single theme, respectively.

Two parts of the corpus also differ with respect to non-[THEME]{.smallcaps} semantic roles. In CHQA-email, two generic semantic roles were defined: [KEYWORD]{.smallcaps}, and [EXCLUDE_KEYWORD]{.smallcaps}. [KEYWORD]{.smallcaps} arguments indicate named entities that are expected to be helpful in finding more specific answers to a question. [EXCLUDE_KEYWORD]{.smallcaps} arguments are those that should be used to exclude some potential answers. While [KEYWORD]{.smallcaps} can be viewed as a generic semantic role and can correspond to more typical semantic roles, such as [AGENT]{.smallcaps}, [PATIENT]{.smallcaps}, [PURPOSE]{.smallcaps}, [EXCLUDE_KEYWORD]{.smallcaps} is unique and is meaningful in a question answering context. Examples in Table [6](#Tab6){ref-type="table"} illustrate these roles. Table 6Illustration of [KEYWORD]{.smallcaps} and [EXCLUDE_KEYWORD]{.smallcaps} semantic roles in question framesQuestion*Is it ok to drink quinine in seltzer water to ease leg cramps?*FrameQuestion type*ease*:[treatment]{.smallcaps}Theme*leg cramps*: [problem]{.smallcaps}Keyword*quinine*: [substance]{.smallcaps}Keyword*seltzer water*: [substance]{.smallcaps}Question*My father is 70 years old, his arteries in the both limbs have blockage.Doctor's suggest to go for amputation but there is high risk in it. Pleasesuggest treatment without amputation.*FrameQuestion type*treatment*:[treatment]{.smallcaps}Theme*arteries in the both limbs have blockage*: [problem]{.smallcaps}ExcludeKeyword*amputation*: [procedure_device]{.smallcaps}The contents of frame elements are shown as *mention*:TYPE pairs

In CHQA-web, we used fine-grained roles, more in line with typical roles used in semantic role labeling. On the other hand, [EXCLUDE_KEYWORD]{.smallcaps} was not considered. The fine-grained roles used are as follows: [agent]{.smallcaps} indicates the entity that performs the action involving the theme. In the clinical domain, inanimate objects, such as drugs, procedures and devices could be agents. For example, in the first example in Table [6](#Tab6){ref-type="table"}, both [keyword]{.smallcaps} arguments can be annotated as [agent]{.smallcaps}s.[locative]{.smallcaps} indicates the location where the action involving the theme occurs (primarily, the body parts). *leg* in the question *parkinson's disease best drugs for legs?* can be annotated with this role in a [treatment]{.smallcaps} frame.[purpose]{.smallcaps} indicates the reason/goal for which the action is performed. *eczema* in the question *how many mg. of zinc daily for eczema patients?* can be annotated with this role in a [usage]{.smallcaps} frame.[patient]{.smallcaps} indicates the experiencer of the action. *baby* in the question *what if a mother quits intravenous drug use at five months what side effect will baby have?* (a [complication]{.smallcaps} frame).[restrictor]{.smallcaps} indicates the context in which the action occurs or a restriction on the type of information being sought. *doctor* in the question *what kind of doctor would i see for calcification?* (a [person_organization]{.smallcaps} frame).[temporal]{.smallcaps} indicates the time at which the action occurs or the duration of the action. *4 years ago* in the question *is zoster vaccine effective if one had shingles 4 years ago?* (an [indication]{.smallcaps} frame)[research]{.smallcaps} indicates the role of [research_cue]{.smallcaps} entities. *literature* in the question *review of literature of cancer stress* (an [information]{.smallcaps} frame).

A question frame can contain multiple arguments with such optional roles. We did not stipulate any semantic restrictions on the named entities that can fill these roles, even though for example, the [PATIENT]{.smallcaps} role is likely to be filled with an entity of [PERSON_POPULATION]{.smallcaps} type, and the [RESEARCH]{.smallcaps} role should be filled with a [RESEARCH_CUE]{.smallcaps} entity.

In CHQA-email, we associated a frame with the attribute [RESEARCH]{.smallcaps} to indicate that the person asking the question is interested in information that goes beyond consumer health information. In CHQA-web, as noted above, we specifically annotated terms indicating such information need as named entities ([RESEARCH_CUE]{.smallcaps}), in order to allow training of machine learning models that automatically learn such phrases.

When there are multiple mentions of a term that fills a specific role, the annotators were instructed to use the mention that is syntactically linked to the question type trigger, if possible. Otherwise, they select the closest mention that precedes the trigger. Similarly, if there are multiple potential triggers, annotators were expected to select the trigger that is syntactically related to the theme or is the trigger closest to it.

The same question is sometimes asked multiple times in the same information request, especially in long requests. Annotators were expected to annotate all instances of such questions. We also found that some questions can be represented from multiple perspectives. Consider the example below: (10)*questions about the effect of L-Leucine.Hello,do you have any introduction about L-Leucine on the effect of treat cancer?If so,could you kindly tell me details?*

This can be formalized in one of two ways: A [treatment]{.smallcaps} frame where *cancer* fills the [theme]{.smallcaps} role and *l-leucine* is an [agent]{.smallcaps} (in essence, corresponding to the question *does l-leucine treat cancer?*)An [indication]{.smallcaps} frame where *l-leucine* is the [theme]{.smallcaps} and *cancer* is a [purpose]{.smallcaps} (corresponding to *is l-leucine indicated for cancer?*)

Annotators were instructed to annotate a single frame in such cases and to take the question topic into consideration in making a decision. In this question, *l-leucine* is the more salient entity (thus, the question topic) and therefore, the frame in which this entity appears as the [THEME]{.smallcaps} element (i.e., the [INDICATION]{.smallcaps} frame) would be preferred. If both entities are equally likely as question topic, we asked the annotators to prefer specific question types over others (e.g., [TREATMENT]{.smallcaps} over [INDICATION]{.smallcaps}, [COMPLICATION]{.smallcaps} over [EFFECT]{.smallcaps}, [CAUSE]{.smallcaps} over [DIAGNOSE_ME]{.smallcaps}).

Annotation confidence estimation {#Sec13}
--------------------------------

It became clear early on that adjudicating annotations in CHQA-email would be significantly difficult, due to the number and length of questions, and the size of annotator pool (21 annotator pairs). This is in contrast to CHQA-web with the smaller number of questions, which are shorter on average, and annotators (4 pairs). Thus, we investigated whether we can estimate confidences for the annotations.

For this purpose, we used two annotation confidence modeling methods: MACE (Multi-Annotator Competence Estimation) \[[@CR67]\] and another probabilistic approach proposed by Passonneau and Carpenter (which we refer to as P&C here) \[[@CR68]\]. Implementations of both methods are freely available and have been successfully applied to crowd-sourced data. They share similarities: they are both generative models based on variations of the item-response model \[[@CR69]\] and learn annotator competence and correct labels in an unsupervised fashion using expectation-maximization (EM). They mainly differ in priors and the EM flavor used, model paramaters, and goals. We refer the reader to respective papers for further details.

We considered annotations of named entities, topic, triggers, and frames for modeling. To simplify matters, we treated each annotation as an independent data instance for MACE and P&C. Once we modeled the annotation confidences using these methods, we used the confidence scores generated to create a new set of annotations. When incorporating these scores, we assumed that if two annotators agreed on a specific annotation, that annotation was correct. For the rest of the annotations on which two annotators did not agree, we followed the following procedure: We calculate the mean average confidence score for each semantic class (i.e., entities, topic, triggers, frames).If the confidence score associated with an individual item is higher than the mean average for its class, it is added to the new set of annotations as long as it is consistent with the annotations already added. Consistency is defined as follows: If the item under consideration is named entity or question trigger, it is always considered consistent, as they are atomic and independent.If it is a question topic, it is considered consistent as long as the underlying named entity has already been added.If it is a question frame, it is consistent as long as its trigger and all its arguments have already been added.

We compared these two methods to two other simple methods: the first (AGREE) only considers the subset of annotations that annotators agreed upon for the new set. The second (IAA_RANK) uses inter-annotator agreement results. For this method, we rank annotators by their inter-annotator agreement with others. Then, for a given question, we prefer the annotations of the annotator ranked higher among the two who annotated the question. Note that none of the methods as used here can distinguish cases where both annotators agree but are both incorrect.

To evaluate the performance of these methods, we ran experiments on CHQA-web, since an adjudicated set of annotations was available. Based on the results we obtained, we generated several sets of annotations for CHQA-email incorporating these methods. We make these sets publicly available in addition to raw annotations by each annotator.

Results and discussion {#Sec14}
======================

In this section, we present and discuss corpus statistics for each part of the corpus, provide an in-depth analysis of the semantic categories annotated, detail inter-annotator agreement and annotation confidence estimation results.

Corpus Statistics {#Sec15}
-----------------

Table [7](#Tab7){ref-type="table"} shows the basic corpus statistics for each part of the corpus. On average, CHQA-email requests are much longer (55.1 tokens vs. 7.5), confirming findings of earlier research \[[@CR3], [@CR8]\]. Standard deviation is high, reflecting a large amount of variation in question length. Table 7Basic corpus statisticsCorpus Part\# questions\# tokensAverageRangeStd. Dev.CHQA-email1,74095,83455.12-42751.3*- Practice*20*- Unadjudicated*1,720CHQA-web8746,5977.53-514.1Total2,614102,43139.22-427136.7

Named entity annotation {#Sec16}
-----------------------

Statistics regarding named entities in the corpus are provided in Table [8](#Tab8){ref-type="table"}. Results for CHQA-email are presented separately for the small practice set and the larger unadjudicated set, because the questions in the latter have been double-annotated and each question is counted twice. The comparison of frequency of the named entity categories is also illustrated in Fig. [2](#Fig2){ref-type="fig"}. Fig. 2The distribution of named entities in CHQA-email and CHQA-web parts of the corpus. [RESEARCH_CUE]{.smallcaps}, annotated in only CHQA-web, is not includedTable 8The distribution of annotated named entity categoriesCategory\# questions% (Rank)\# questions% (Rank)\# questions% (Rank)*CHQA-emailCHQA-webPracticeUnadjudicated*[anatomy]{.smallcaps}3112.8 (4)5,33915.8 (2)15310.8 (3)[cellular\_]{.smallcaps} [entity]{.smallcaps}00 (17)2240.7 (16)130.9 (12)[diagnostic\_]{.smallcaps} [procedure]{.smallcaps}31.2 (8)9672.9 (8)1017.2 (4)[drug_supplement]{.smallcaps}2610.8 (5)3,2649.7 (4)23716.8 (2)[food]{.smallcaps}31.2 (8)4741.4 (11)352.5 (11)[gene_protein]{.smallcaps}10.4 (16)1560.5 (17)90.6 (14)[geographic\_]{.smallcaps} [location]{.smallcaps}20.8 (13)4551.4 (13)30.2 (17)[lifestyle]{.smallcaps}20.8 (13)4381.3 (14)443.1 (9)[measurement]{.smallcaps}31.2 (8)3311.0 (15)100.7 (13)[organism\_]{.smallcaps} [function]{.smallcaps}31.2 (8)4691.4 (12)664.7 (6)[organization]{.smallcaps}72.9 (7)5761.7 (9)10.1 (18)[person\_]{.smallcaps} [population]{.smallcaps}3614.9 (2)3,76311.2 (3)604.2 (7)[problem]{.smallcaps}7531.0 (1)11,71134.7 (1)47633.7 (1)[procedure\_]{.smallcaps} [device]{.smallcaps}3213.2 (3)2,4817.4 (5)997.0 (5)[profession]{.smallcaps}20.8 (13)1,1443.4 (7)80.6 (15)[research_cue]{.smallcaps}\-\-\--40.3 (16)[substance]{.smallcaps}135.4 (6)1,4664.3 (6)564.0 (8)[other]{.smallcaps}31.2 (8)4891.5 (10)382.7 (10)Total242100.033,747100.01,413100.0Average12.19.81.6Range1-351-841-5Note that questions in the unadjudicated set are counted twice since this set is double-annotated

As expected, the distribution of named entity categories and the average number of annotations per question in CHQA-email are similar to those reported for CHQ-NER, which CHQA-email supersedes. For the short questions in CHQA-web, the average number of entities per question is much lower (1.6). [DRUG_SUPPLEMENT]{.smallcaps} and [DIAGNOSTIC_PROCEDURE]{.smallcaps} terms appear more frequently in CHQA-web, while categories like [PERSON_POPULATION]{.smallcaps}, [ORGANIZATION]{.smallcaps}, [PROFESSION]{.smallcaps}, which often provide background information, appear less frequently than in CHQA-email. The distribution also confirms findings from earlier studies that consumer questions focus mostly on diseases and symptoms (i.e., [PROBLEM]{.smallcaps} category).

A small number of named entity annotations were added to CHQA-email (Unadjudicated) or deleted by annotators, increasing the number of annotations in this set from 33,494 to 33,747. [PROBLEM]{.smallcaps} category had the highest number of additions (141), and [ORGANIZATION]{.smallcaps} had the highest number of deletions (12), though additions/deletions often amounted to a very small percentage of the entities in a given category. Additions included problems like *pain in period* and drug classes like *allopathic medicines*.

[RESEARCH_CUE]{.smallcaps} category was only annotated in CHQA-web. In CHQA-email, [RESEARCH]{.smallcaps} attribute assigned to question frames indicates the same information without explicitly marking the mention. The total number of [RESEARCH]{.smallcaps} attribute annotations are 2 and 109 in CHQA-email (Practice) and CHQA-email (Unadjudicated), corresponding to 0.8% and 0.3% of all the entities, respectively, indicating a distribution similar to that of [RESEARCH_CUE]{.smallcaps} in CHQA-web.

Question trigger/type annotation {#Sec17}
--------------------------------

Statistics regarding question triggers/types in the corpus are provided in Table [9](#Tab9){ref-type="table"}. [TREATMENT]{.smallcaps} triggers are most common in CHQA-email by a significant margin. In CHQA-web, [INFORMATION]{.smallcaps} triggers are most common, though its margin over the next most frequent type, [CAUSE]{.smallcaps}, is not as large. There are differences in the distribution of question types between the two parts: most significant are [PERSON_ORGANIZATION]{.smallcaps} and [PROGNOSIS]{.smallcaps} question types, which appear much more frequently in CHQA-email, and [CAUSE]{.smallcaps}, [LOCATION]{.smallcaps}, [ACTION]{.smallcaps}, and [INDICATION]{.smallcaps} question types, which occur more frequently in CHQA-web. Some of these differences can be explained by the question selection methodology. For example, in constructing CHQA-web, the same number of questions were sampled using different *wh*-words. *where* questions often contain [LOCATION]{.smallcaps} questions, which occurs in large quantity in CHQA-web, but is very rare in CHQA-email. The comparison of frequency of question trigger types in CHQA-email and CHQA-web is illustrated in Fig. [3](#Fig3){ref-type="fig"}. The distribution of question types in CHQA-email is similar to that presented for GARD dataset in Roberts et al. \[[@CR10]\]. Fig. 3The distribution of question trigger types in CHQA-email and CHQA-web parts of the corpus. The question type categories in CHQA-web is used and some of the CHQA-email types are merged with their supertypes (e.g., [SUPPORT_GROUP]{.smallcaps} is merged with [PERSON_ORGANIZATION]{.smallcaps}) for simplicityTable 9The distribution of annotated question triggers/typesCategory\# questions\# questions% (Rank)\# questions% (Rank)*CHQA-emailCHQA-webPracticeUnadjudicatedGeneral question types*[comparison]{.smallcaps}1521.2 (19)252.8 (11)[information]{.smallcaps}169215.6 (2)14716.7 (1)[time]{.smallcaps}\-\--404.5 (9)[other_question]{.smallcaps}01653.7 (7)00 (24)*Problem question types*[cause]{.smallcaps}42515.7 (3)9510.8 (2)[complication]{.smallcaps}1661.5 (16)323.6 (10)[diagnose_me]{.smallcaps}\-\--111.3 (19)[diagnosis]{.smallcaps}01663.8 (6)161.8 (15)[effect]{.smallcaps} ([association]{.smallcaps})01112.5 (10)111.3 (19)[frequency]{.smallcaps}0200.5 (29)\--[inheritance]{.smallcaps}0872.0 (14)\--[lifestyle_diet]{.smallcaps}0501.1 (20)151.7 (16)[location]{.smallcaps}080.2 (32)799.0 (4)[person_organization]{.smallcaps}12245.1 (4)171.9 (14)[prevention]{.smallcaps}0421.0 (21)40.5 (22)[prognosis]{.smallcaps}12054.6 (5)141.6 (17)[support_group]{.smallcaps}0120.3 (31)\--[susceptibility]{.smallcaps}0661.5 (16)495.6 (7)[symptom]{.smallcaps}0801.8 (15)182.0 (13)[treatment]{.smallcaps}91,24328.1 (1)879.9 (3)*Intervention question types*[action]{.smallcaps}0260.6 (28)414.7 (8)[alternative]{.smallcaps}0350.8 (22)00 (24)[contraindication]{.smallcaps}1330.7 (25)242.7 (12)[cost]{.smallcaps}1200.5 (29)20.2 (23)[dosage]{.smallcaps}0340.8 (23)\--[indication]{.smallcaps}11112.5 (10)758.5 (5)[ingredient]{.smallcaps}11232.8 (9)70.8 (21)[interaction]{.smallcaps}0601.4 (18)131.5 (18)[long_term_effect]{.smallcaps}1330.7 (25)\--[overdose]{.smallcaps}180.2 (32)\--[side_effect]{.smallcaps}11092.5 (12)\--[storage_disposal]{.smallcaps}0310.7 (27)\--[tapering]{.smallcaps}0340.8 (23)\--[usage]{.smallcaps}01333.0 (8)606.8 (6)[drug_question]{.smallcaps}0992.2 (13)00 (24)Total254,429882Average1.251.291.01Range1-41-151-2Note that questions in the unadjudicated set are counted twice since this set is double-annotated

We analyzed the distribution of trigger expressions for each question type. A subset of results is provided in Table [10](#Tab10){ref-type="table"}. Only top 10 triggers, if they occur more than once, are listed. We list the triggers without any lemmatization or spelling correction. Our analysis indicates that trigger lists for question types often have a long tail. In CHQA-email, [TREATMENT]{.smallcaps}, [COST]{.smallcaps}, and [CAUSE]{.smallcaps} question types have the least uniform distribution (i.e., relatively few triggers are used), while in CHQA-web, these question types are [LOCATION]{.smallcaps} and [CAUSE]{.smallcaps}. There is a slight preference for verbal triggers in CHQA-web as compared with CHQA-email. Light verbs, such as *get*, *help*, *have*, and *do* are the most heterogeneously annotated triggers, indicating 13, 11, 11, and 11 different question types, respectively, in CHQA-email. In CHQA-web, these triggers are *have*, *why*, *when*, and *take*, indicating a mix of light verbs and *wh*-words, to some extent reflecting the question selection process for this part of the corpus. Table 10The distribution of annotated question triggersCategory\#Top triggers\#Top triggers*CHQA-email (Unadjudicated)CHQA-webGeneral question types*[comparison]{.smallcaps}28*difference (10), better, differences, better then, vs, versus, similiar, like, comparison, compared*20*better (5), most effective*[information]{.smallcaps}272*information (144), info, know, help, is, research, mean, learn*52*what is (56), is, normal, why, which is, called, what, means, mean, ?*[time]{.smallcaps}\--23*after (8), when, stay, take, start, how long*[other_question]{.smallcaps}131*danger (5), cost (5), too low, low, long*0-*Problem question types*[cause]{.smallcaps}70*cause (76), causes, caused, causing, why, reason*26*why (31), cause, causes, when, is, ?*[complication]{.smallcaps}40*cause (6), complications (6), risks, effect, caused, affect*29*result (2), after, affect*[diagnose_me]{.smallcaps}\--10*problem (2)*[diagnosis]{.smallcaps}85*test (13), diagnosis(13), tests, testing, tested, what, for, exams, detected*11*show (6)*[effect]{.smallcaps} ([association]{.smallcaps})69*effect(7), interfere, due to, connection, cause, related, link, affect*8*affect (3), do with*[frequency]{.smallcaps}14*common (5), uncommon*-[inheritance]{.smallcaps}54*genetic (9), passed, inherited, chance, carriers, passed down, pass*-[lifestyle_diet]{.smallcaps}37*eat (5), food, maintain, is, help, exercises, do, diet, avoid*11*need (2), good, feed, drink*[location]{.smallcaps}7*most common location (2)*21*where (23), where is, located, where are, go, come from*[person\_ organization]{.smallcaps}114*doctor (12), where, contact, find, specialist, place, study, go, doctors, anyone*13*who (3), performs, administer*[prevention]{.smallcaps}22*prevent (12), protect, prevention, prevented, avoid, privention*2*prevent (3)*[prognosis]{.smallcaps}148*how long (8), prognosis, go away, recovery, life expectancy, happen, lead to, continue*13*happen (2)*[support_group]{.smallcaps}10*support (3)*-[susceptibility]{.smallcaps}41*get (10), risk, contagious, expose, transmitted, start again, spread, passed, occur, go to the hospital*29*contagious (8), affected, gets, common, affect, risk*[symptom]{.smallcaps}51*symptoms (24), signs, normal, symptom, neck symptoms, mouth symptoms, heart symptoms, get, feeling, do*14*know (3), symptoms, affect*[treatment]{.smallcaps}303*treatment (202), help, do, cure, treatments, treat, medicine, stop, for, take*46*treat (9), help, used, lower, for, cure, treatment, stop, reduce, increase*Category\#Top triggers\#Top triggers*CHQA-email (Unadjudicated)CHQA-webIntervention question types*[action]{.smallcaps}21*how long (3), help, half life, effects*29*why (4), works, work, used, responsible, help, go, controls*[alternative]{.smallcaps}25*alternative (6), take, superior, substitute, replacements, alternatives*0-[contraindication]{.smallcaps}23*take (5), use, should not take, hurt, have*22*bad (2), after (2)*[cost]{.smallcaps}5*cost (13), generic, prices*1*cost (2)*[dosage]{.smallcaps}19*dosage (10), administration rates, lowest starting dose, dose, concentration*0-[indication]{.smallcaps}73*help (10), for, used, take, prescribed, get*34*need (9), why, use, take, get, used, have, for*[ingredient]{.smallcaps}38*is (26), contain, ingredients, in, free, contains, chemicals, ingredient, are*4*contain (3), is*[interaction]{.smallcaps}41*together (5), take, safe*12*when taking (2)*[long_term_effect]{.smallcaps}26*safe (2), long term effects, long term adverse reactions, last, damage, contributed, cause*0-[overdose]{.smallcaps}8-0-[side_effect]{.smallcaps}60*side effects (16), cause, side affect, side effect, effect, have, effects, causes, affect*0-[storage_disposal]{.smallcaps}21*storage (3), stability (3), mixing (3), storing, kept, keep, glycogen storage disease, effective*0-[tapering]{.smallcaps}28*cut back (2), orwithdraw, tapering, withdrawal, weaning, wean*0-[usage]{.smallcaps}89*use (8), take, taken, taking, get, instructions, how long, doing*42*use (12), stop, given, take, dosage*Numbers in the second and fourth columns are unique counts of triggers used for the corresponding category. Only triggers that occur at least twice are shown. The most frequent trigger for a given category is indicated with its frequency in parentheses (when this frequency is 2, all triggers given occur twice)

We asked annotators to indicate their proposed question types when annotating [OTHER_QUESTION]{.smallcaps} and [DRUG_QUESTION]{.smallcaps} categories in CHQA-email. After the annotations were completed, we manually categorized the small number of proposed types the annotators had specified. These types are provided in Table [11](#Tab11){ref-type="table"}. Reference ranges for diagnostic tests, availability of drugs and other interventions as well as [DIAGNOSE_ME]{.smallcaps} (which we adopted later for CHQA-web) were among the most frequent. In general, the annotators were not consistent in proposing new question types; therefore, these results should be interpreted with caution. Also note that the annotation guidelines sometimes indicate a particular question type for a specific kind of information request annotated with one of these two types (e.g., [INFORMATION]{.smallcaps} for Manufacturer); however, these were missed by some annotators, indicating potential annotation errors. Table 11The distribution of proposed question types annotated as [OTHER_QUESTION]{.smallcaps} or [DRUG_QUESTION]{.smallcaps}Category\# questionsBrief desription[other_question]{.smallcaps}Antidote2How to deal with a chemicalAvailability9Availability of an intervention on the market, where to get itComplication management1How to fix an issue arising from a procedureContraindicated1What is contraindicated for a diseaseDiagnose Me5Diagnosis given a list of symptomsDuration3How long for a procedure/treatmentFertility1Possible to have children with existing conditionFunction1How a body part worksGene-disease association2Association between a gene and a diseaseHistory3History of a diseaseIncubation1Incubation period for a diseaseInterpretation5Lab result interpretationPost-procedure management3Management options after a procedurePreparation2How to prepare for a lab testProcedure follow-up7Whether procedures are still needed after a problem is solvedProgression3How a disease progressesTest result range10Reference values for a lab test/procedure[drug_question]{.smallcaps}Clinical trial3Trials for a drugCoindication1Whether to use a drug with anotherCoverage5Whether insurance pays for a drugEffect duration3How long the effect lastsForm4What form the drug comes inManufacturer6Manufacturer of a drugPackaging1How a drug is packagedPharmacokinetics6How long it takes for a drug to have effectPotency3Whether a drug retains its potency after a time periodPrescription4Whether a prescription is neededStability1Whether a drug is stable when dilutedTransmission3Whether a drug is transmitted through body fluids

Question frame annotation {#Sec18}
-------------------------

Statistics regarding question frame types in the corpus are provided in Table [12](#Tab12){ref-type="table"}. For CHQA-email (Practice), the results are the same as those for question triggers, indicating that each trigger in this set was associated with a single frame. In CHQA-email (Unadjudicated) and CHQA-web, a small proportion of triggers were used by several frames. The maximum number of frames indicated by a single trigger was 6. On average, a single [SIDE_EFFECT]{.smallcaps} trigger was annotated with highest number of frames, indicating that consumers were often interested in side effects of multiple drugs in the same question. The comparison of frequency of question frame categories in CHQA-email and CHQA-web is illustrated in Fig [4](#Fig4){ref-type="fig"}. Fig. 4The distribution of question frames in CHQA-email and CHQA-web parts of the corpus. The question frame categories in CHQA-web is used and some of the CHQA-email types are merged with their supertypesTable 12The distribution of annotated question frame categoriesCategory\# questions\# questions% (Rank)\# questions% (Rank)*CHQA-emailCHQA-webPracticeUnadjudicatedGeneral question types*[comparison]{.smallcaps}1521.1 (19)252.7 (12)[information]{.smallcaps}173615.7 (2)14816.5 (1)[time]{.smallcaps}\-\--404.5 (9)[other_question]{.smallcaps}01723.7 (7)00 (24)*Problem question types*[cause]{.smallcaps}42635.6 (3)10011.1 (2)[complication]{.smallcaps}1671.4 (17)323.6 (10)[diagnose_me]{.smallcaps}\-\--111.2 (20)[diagnosis]{.smallcaps}01803.8 (6)161.8 (15)[effect]{.smallcaps} ([association]{.smallcaps})01122.4 (12)121.3 (19)[frequency]{.smallcaps}0210.5 (29)\--[inheritance]{.smallcaps}0901.9 (14)\--[lifestyle_diet]{.smallcaps}0511.1 (20)151.7 (16)[location]{.smallcaps}080.2 (32)798.8 (4)[person_organization]{.smallcaps}12375.1 (4)171.9 (14)[prevention]{.smallcaps}0481.0 (21)40.5 (22)[prognosis]{.smallcaps}12094.5 (5)141.6 (17)[support_group]{.smallcaps}0140.3 (31)\--[susceptibility]{.smallcaps}0671.4 (17)495.5 (7)[symptom]{.smallcaps}0831.8 (15)182.0 (13)[treatment]{.smallcaps}91,29827.7 (1)9010.0 (3)*Intervention question types*[action]{.smallcaps}0260.6 (28)434.8 (8)[alternative]{.smallcaps}0390.8 (22)00 (24)[contraindication]{.smallcaps}1340.7 (26)273.0 (11)[cost]{.smallcaps}1200.4 (30)20.2 (23)[dosage]{.smallcaps}0360.8 (23)\--[indication]{.smallcaps}11272.7 (10)788.7 (5)[ingredient]{.smallcaps}11272.7 (10)70.8 (21)[interaction]{.smallcaps}0731.6 (16)131.5 (18)[long_term_effect]{.smallcaps}1340.7 (26)\--[overdose]{.smallcaps}180.2 (32)\--[side_effect]{.smallcaps}11342.9 (9)\--[storage_disposal]{.smallcaps}0360.8 (23)\--[tapering]{.smallcaps}0350.7 (25)\--[usage]{.smallcaps}01433.1 (8)606.7 (6)[drug_question]{.smallcaps}01042.2 (13)00 (24)Total254,684900Range1-41-181-2Average1.251.361.03

Table [13](#Tab13){ref-type="table"} shows the counts of semantic roles in frames. The percentage of frame annotations involving a non-[THEME]{.smallcaps} role was approximately 68% in CHQA-email and 46% in CHQA-web. This difference is to be expected, as longer CHQA-email questions often provide more context that may be relevant for answering questions. The most frequently used semantic role in CHQA-web was the unspecific [RESTRICTOR]{.smallcaps}. Considering that this role is largely similar to [KEYWORD]{.smallcaps} and not very informative, fine-grained annotation of semantic roles ([AGENT]{.smallcaps}, [PATIENT]{.smallcaps}, etc.) may not provide much advantage over simply using coarse-grained [KEYWORD]{.smallcaps} when it comes to question understanding. [EXCLUDE_KEYWORD]{.smallcaps} role was rarely used in CHQA-email, suggesting that its utility for answering consumer health questions may be limited, and was later dropped for CHQA-web. Table 13The distribution of frame semantic rolesCategory\# questionsRange\# questionsRange\# questionsRange*CHQA-emailCHQA-webPracticeUnadjudicated*[theme]{.smallcaps}271-34,8601-79581-5[keyword]{.smallcaps}181-22,9590-9\--[exclude_keyword]{.smallcaps}0-1070-6\--[agent]{.smallcaps}\-\-\--910-2[locative]{.smallcaps}\-\-\--850-2[patient]{.smallcaps}\-\-\--580-1[purpose]{.smallcaps}\-\-\--240-1[restrictor]{.smallcaps}\-\-\--1850-3[temporal]{.smallcaps}\-\-\--280-1[research]{.smallcaps}\-\-\--40-1

Question topic annotation {#Sec19}
-------------------------

We only annotated question topic in CHQA-email, as this element almost always corresponds to the theme element of the question in the short CHQA-web questions. On average, 1.8 question topics were annotated per question. The maximum number of topic mentions annotated for a single question was 17.

Inter-annotator agreement {#Sec20}
-------------------------

We calculated pairwise inter-annotator agreement, using micro-average F~1~ score when one set of annotations is taken as the gold standard. Agreement was calculated for named entities, question triggers/types, question topics, and frames. Exact span match criterion was used to compare mentions (named entities and question triggers).

We calculated frame agreement in several ways. For *full frame* agreement calculation, we considered the question trigger/type and all semantic roles ([KEYWORD]{.smallcaps}, [AGENT]{.smallcaps}, etc.). For *core frame* agreement, we considered only the [THEME]{.smallcaps} role in addition to question trigger/type. In addition, frame agreement calculation can be based on question trigger mentions or normalized question types indicated by these mentions. Combinations of these options, consequently, led to the following frame agreement types: *Full frame w/ trigger*, *Full frame w/ type*, *Core frame w/ trigger*, and *Core frame w/ type*. We consider *Core frame w/ type* as the most relevant for QA, as identifying specific words used to express a question precisely is generally not needed for accurately answering it.

We did not consider agreement on practice sets for each part of the corpus. We also did not calculate named entity agreement on CHQA-email (Unadjudicated), since this largely overlaps with CHQ-NER and the inter-annotator agreement for named entities in that set were reported earlier \[[@CR12]\]. The results of inter-annotator agreement calculation are provided in Table [14](#Tab14){ref-type="table"} and illustrated in Figs. [5](#Fig5){ref-type="fig"} and [6](#Fig6){ref-type="fig"}. Fig. 5Inter-annotator agreement for various question elements in CHQA-email. Exact match criterion is used as the basis of agreementFig. 6Inter-annotator agreement for various question elements in CHQA-web. Exact match criterion is used as the basis of agreementTable 14Inter-annotator agreement resultsCategoryAverageRangeAverageRange*CHQA-emailCHQA-webUnadjudicated*Avg. \# of questions shared81.936-120540540-540Named entity\--0.720.66-0.78Question trigger0.370.18-0.520.600.46-0.66Question type0.580.39-0.690.740.65-0.81Full frame w/ trigger0.220.08-0.340.410.33-0.48Core frame w/ trigger0.270.11-0.410.480.38-0.56Full frame w/ type0.320.15-0.460.540.47-0.58Core frame w/ type0.410.22-0.560.640.55-0.70Question topic0.710.61-0.87\--Inter-annotator agreement is calculated as the micro-average F1 score when one set of annotations is taken as the gold standard

Inter-annotator agreement in CHQA-email is overall low. The highest agreement is for question topics (0.71) and the lowest is for full frame agreement (0.22), which considers named entity and trigger mentions, and all semantic roles (*Full frame w/ trigger*). Frame annotation in general is challenging as the results indicate, but the agreement is somewhat improved when the agreement only focuses on core frame elements, question type and theme (0.41 with *Core frame w/ type*). The low agreement for frames is not unexpected, as they can involve many parts, each potentially leading to disagreement. In particular, annotators had difficulty in agreeing on the exact boundaries of trigger mentions (0.37), one of the major components of the frames. When the matching criterion is changed to allow mention overlap (approximate match), average question trigger agreement increases from 0.37 to 0.45, full frame agreement from 0.22 to 0.28, and core frame with type agreement from 0.41 to 0.44. While these figures are still low, they suggest that more strict guidelines may be useful in annotating triggers. In contrast to named entities which are often expressed with specific part-of-speech elements, triggers are lexically and syntactically more heterogeneous and ambiguous, especially in consumer health questions; thus, developing such guidelines may be difficult. Analyzing inter-annotator agreement for triggers of each question type, we find that the agreement is generally higher for triggers of the frequent question types (Table [15](#Tab15){ref-type="table"}). The question types ranked highest in terms of inter-annotator agreement for triggers are [CAUSE]{.smallcaps} (0.60), [TREATMENT]{.smallcaps} (0.52), [PREVENTION]{.smallcaps} (0.44), and [PERSON_ORGANIZATION]{.smallcaps} (0.43), while for the rare types, the agreement is very low or even zero (for [SUPPORT_GROUP]{.smallcaps} and [OVERDOSE]{.smallcaps}). Table 15Inter-annotator agreement broken down by question types and corresponding triggersCategoryTriggerTypeTriggerType*CHQA-emailCHQA-webGeneral question types*[comparison]{.smallcaps}0.280.430.660.77[information]{.smallcaps}0.370.510.650.75[time]{.smallcaps}\--0.470.65[other_question]{.smallcaps}0.230.390.000.00*Problem question types*[cause]{.smallcaps}0.600.640.630.76[complication]{.smallcaps}0.170.210.580.64[diagnose_me]{.smallcaps}\--0.720.82[diagnosis]{.smallcaps}0.300.480.510.72[effect]{.smallcaps} ([association]{.smallcaps})0.350.450.170.17[frequency]{.smallcaps}0.200.30\--[inheritance]{.smallcaps}0.300.46\--[lifestyle_diet]{.smallcaps}0.020.250.320.37[location]{.smallcaps}0.200.200.600.85[person_organization]{.smallcaps}0.430.630.180.63[prevention]{.smallcaps}0.440.510.500.50[prognosis]{.smallcaps}0.250.490.410.77[support_group]{.smallcaps}0.000.00\--[susceptibility]{.smallcaps}0.260.340.570.73[symptom]{.smallcaps}0.260.450.530.65[treatment]{.smallcaps}0.520.750.760.86*Intervention question types*[action]{.smallcaps}0.030.190.570.60[alternative]{.smallcaps}0.180.22\--[contraindication]{.smallcaps}0.100.250.570.67[cost]{.smallcaps}0.400.401.001.00[dosage]{.smallcaps}0.230.37\--[indication]{.smallcaps}0.150.290.480.75[ingredient]{.smallcaps}0.360.830.500.50[interaction]{.smallcaps}0.200.730.570.78[long_term_effect]{.smallcaps}0.220.30\--[overdose]{.smallcaps}0.000.33\--[side_effect]{.smallcaps}0.310.39\--[storage_disposal]{.smallcaps}0.190.35\--[tapering]{.smallcaps}0.130.36\--[usage]{.smallcaps}0.080.400.620.72[drug_question]{.smallcaps}0.140.28\--

Compared to question triggers, the agreement on question types is much higher, indicating that annotators can identify the information request in abstract, but have difficulty in annotating the relevant piece of text. We also note that agreement for question types is lower than that reported for GARD (0.58 and 0.74 in this study vs. 0.81) \[[@CR10]\]. This is partly due to the fact that the number of question types is significantly higher in our case and also to the fact that GARD questions are in general much shorter and well-formed. On the whole, these results point out that it would be more practical to focus on annotating question types only, instead of attempting to also precisely identify the question triggers. However, we should also note that machine learning approaches are likely to benefit from mention-level trigger annotations.

Agreement in CHQA-web is consistently higher than that in CHQA-email by about 0.2 points. Trends are similar for different semantic classes, confirming our basic intuition that annotating these shorter questions is easier, compared to CHQA-email. Agreement for named entities (0.72) is consistent with that reported for CHQ-NER (0.71) \[[@CR12]\], although given the trends, we would have expected it to be higher. This may be attributed to the fact named entity annotation for this part of the corpus was not performed as a separate study, and annotators may not have been as diligent in following the strict guidelines for named entity annotation. In this part of the corpus, inter-annotator agreement for question triggers is generally higher than that in CHQA-email, and is more evenly distributed between frequent and rare question types: among the top four question types are [COST]{.smallcaps}, [DIAGNOSE_ME]{.smallcaps}, and [COMPARISON]{.smallcaps}, which are relatively rare, as well as [TREATMENT]{.smallcaps}, the third most frequent trigger type in this subset (Table [15](#Tab15){ref-type="table"}). Agreement on question types follows a similar pattern and, for frequent question types, reaches as high as 0.86 ([TREATMENT]{.smallcaps}).

Annotation confidence estimation {#Sec21}
--------------------------------

The evaluation results of annotation confidence estimation for CHQA-web are provided in Table [16](#Tab16){ref-type="table"}. These results have been obtained by comparing the estimation method results with the adjudicated results. We ran the same estimation methods on CHQA-email (Unadjudicated) and provide the resulting data; however, we were unable to evaluate those results, as no gold standard exists for comparison. Table 16Annotation confidence estimation in CHQA-webMethodPrecisionRecallF~1~AGREE0.990.660.79IAA_RANK (*Full frame w/ trigger*)0.780.800.79IAA_RANK (*Core frame w/ type*)0.850.840.84MACE0.820.860.84MACE (Reliability Rank)0.830.830.83P&C0.870.790.83P&C (Reliability Rank)0.810.820.82

The results show that the baseline (AGREE: taking simple agreement of annotators as indication of confidence) already achieves an agreement of 0.79 with the adjudicated results. The precision of 0.99 indicates that a small number of annotations that the annotators agreed upon were discarded later in adjudication. All other methods improve on the low recall of the baseline (0.66), while leading to some precision loss. IAA_RANK uses the ranking of annotators by their average agreement score, and can be based on any of the agreement categories described earlier. Because frame annotations incorporate other atomic annotations (named entities, triggers), we ran IAA_RANK with two frame agreement results. The first ranks the annotators by their average agreement for full frame with triggers, and the second by their agreement for core frame with types. The latter led to best confidence estimation for CHQA-web (0.844).

The results obtained with MACE \[[@CR67]\] and P&C \[[@CR68]\] methods were similar to each other, although MACE had a slight edge and provided confidence estimation that is very close to the best results (0.841 vs. 0.844). Using the annotator reliability ranking provided by MACE and P&C, we obtained results that are slightly lower than their confidence score-based counterparts (0.83 vs. 0.84 and 0.82 vs. 0.83). Overall, the results obtained by these two methods are lower than the results reported for other corpora \[[@CR67], [@CR68]\]. We attribute this partly to the fact that crowdsourcing is used in those cases; with a larger pool of annotators who annotate all instances, it is likely that these methods would perform better. Furthermore, compared to the type of annotations they consider (e.g., word senses, textual entailment pairs), our annotations (in particular, frames) are significantly more complex. In fact, when we only focused on the named entities in CHQ-NER (1548 questions) (i.e., less complex annotations), we obtained the best results with MACE. As noted earlier, as input to these two methods, we made the simplifying assumption that each annotation is independent. A representation that better reflects the compositional nature of frames may also lead to better results.

We ran the same methods on CHQA-email (Unadjudicated) and provide this part of the corpus in several versions: AGREE, IAA_RANK (both *Full frame w/trigger* and *Core frame w/ type*), MACE, and P&C subsets. In addition, we provide MACE and P&C confidence estimations for each annotation. This can enable further research in developing more advanced methods that estimate annotation confidence. For example, the confidence scores generated by MACE and P&C and the output of other simpler methods can be used as features to learn to predict confidence. Confidence scores can also be used in an active learning framework, where the annotator is presented only with the annotations with moderate confidence, reducing adjudication load. Distinguishing high from low confidence items can also benefit training and evaluation: for example, a system can be penalized less for an incorrect response, when the annotation is labeled with low confidence \[[@CR68]\].

Conclusion {#Sec22}
==========

We presented a corpus of consumer health questions annotated for various semantic classes: named entities, question triggers/types, question topics, and frames. The questions cover a wide spectrum, from short questions with little to no context to long questions filled with irrelevant information, reflecting all the complexity and difficulty of consumer health questions. With respect to question understanding and answering, they present different challenges and different approaches may be needed. The corpus is the first focusing on annotation of real consumer questions, and with its size, the number and types of annotations included, it represents a rich resource for consumer health QA. The corpus, annotation guidelines and various analyses are publicly available at <https://bionlp.nlm.nih.gov/CHIQAcollections/CHQA-Corpus-1.0.zip>.

Our corpus has some limitations. Our conceptualization of question understanding and our goals have evolved over time and the corpus reflects this to some extent. Two parts of the corpus are largely similar, but there are also differences. In most cases, these differences can be reconciled with some automatic processing, as in question types that are merged in the other part of the corpus or non-[THEME]{.smallcaps} semantic roles. Some aspects are more difficult to reconcile, however. For example, we ignored diagnosis-seeking questions ([DIAGNOSE_ME]{.smallcaps}) for a long time, since they were considered outside the scope of our work. More recently, we began considering these questions but annotated them only in CHQA-web. A large portion of the corpus has not been adjudicated due to personnel/time constraints, which may limit its usefulness. To address this, we experimented with several methods of annotation confidence estimation and make these estimates available, which could stimulate research in better understanding annotator behavior and automatic adjudication.

In ongoing and future work, we plan to expand this corpus on several other semantic dimensions. For example, we are currently normalizing named entities in our corpus by mapping them to the corresponding UMLS Metathesaurus concepts. By addressing the lexical variability in named entities, this can improve question understanding. In earlier work, we found that coreference played a major role in consumer health question understanding \[[@CR9]\], and we plan to add coreference annotations to a subset of CHQA-email. Similarly, we annotated spelling errors on a smaller set of long questions in an earlier study \[[@CR58]\], and we also plan to add such annotations to this corpus.

<http://www.mdedge.com/jfponline/clinical-inquiries>

<https://rarediseases.info.nih.gov/>

In previous work, we used the terms *focus* \[[@CR11]\] and *topic* \[[@CR57]\] to refer to this element. In this paper, we use the term *topic*.

Note, however, that named entities are reconciled since they have been mostly inherited from CHQ-NER \[[@CR12]\].
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